Infosys vs Cognizant: A Fierce Legal Clash Over Market Control

The legal battle between two IT titans, India’s Infosys and US-based Cognizant Technology Solutions, has escalated significantly, reaching a new level with Infosys filing fresh charges in a US district court. The charges accuse Cognizant of using monopolistic tactics to suppress competition, particularly in the healthcare software market through its Cognizant TriZetto Software Group platform.

The Allegations: Infosys Accuses Cognizant of Anti-Competitive Practices

Infosys has filed a new complaint in a Dallas, Texas court, intensifying the ongoing legal conflict with Cognizant. According to Infosys, Cognizant leveraged its market power to stifle competition and maintain dominance in the healthcare software industry. The latest charges, outlined in a 35-page document filed on March 31, 2025, claim that Cognizant used anti-competitive practices, including inflating prices, reducing product output, and blocking competitors from entering the market.

The filing highlights how Cognizant allegedly employed restrictive non-disclosure agreements (NDAAs) to hinder the growth of competitors. Infosys also claims that Cognizant withheld crucial software training for its products, such as QNXT and Facets, and engaged in activities to undermine Infosys’s healthcare platform, Helix. Moreover, Infosys accuses Cognizant of using “most favored vendor” (MFV) agreements to cement its dominant position in the market, thereby preventing competitors from thriving.

Infosys’s complaint stresses that these tactics are nothing short of an attempt at monopolization, with the company requesting the court to dismiss Cognizant’s motion to have the case thrown out. Infosys further argues that Cognizant’s actions represent “unreasonable restraint of trade,” a violation of antitrust laws.

A Bitter History of Corporate Rivalry

This legal dispute is part of a broader, ongoing rivalry between the two companies. The conflict began in August 2024 when Cognizant accused Infosys of stealing trade secrets related to TriZetto, a software company owned by Cognizant. In response, Infosys filed an antitrust counterclaim in January 2025, alleging that Cognizant’s anti-competitive behavior was hindering fair market competition.

The dispute has also become personal, with Infosys accusing Cognizant’s CEO, Ravi Kumar S, of intentionally delaying the launch of Infosys’s Helix platform during his tenure at Infosys and poaching critical executives after joining Cognizant in 2023. However, Cognizant has dismissed Infosys’s accusations as “preposterous” and “absurd,” maintaining that Infosys misused its intellectual property.

The competition between the two companies is fierce. In 2023, Cognizant reported \$19.7 billion in revenue, while Infosys followed closely with \$18.6 billion. The two companies have long competed for the coveted second spot in India’s IT services export market.

What Undercode Say: A Closer Look at the Legal Battle

This legal war between Infosys and Cognizant reflects much more than just a corporate rivalry. The charges brought by Infosys point to deeper issues within the global IT services market. The allegations of monopolistic behavior suggest that larger firms are exerting increasing control over specialized sectors like healthcare software, limiting market entry for smaller, agile players.

Moreover, the use of non-disclosure agreements (NDAAs) and “most favored vendor” (MFV) agreements highlights how dominant players in the market can manipulate contracts to stifle competition. These practices can make it difficult for new entrants to gain a foothold, especially in niche but growing markets like healthcare software.

This ongoing dispute also underscores the shifting dynamics in the global IT services landscape, particularly in India, where Infosys and Cognizant are key players. As both companies push for dominance, their strategies have significant implications for the broader market, affecting everything from pricing structures to access to cutting-edge technology.

This case could serve as a bellwether for future antitrust challenges within the IT services industry, particularly in sectors that are rapidly evolving, such as healthcare tech. Given the increasing consolidation of power in the hands of a few major players, the outcome of this case may determine how aggressively the industry is regulated moving forward.

Fact Checker Results: Verifying the Claims

✅ The filing by Infosys against Cognizant has been confirmed and is a genuine legal document, as reported by sources like Economic Times and other media outlets.
✅ Infosys’s claims of inflated pricing and restrictive practices like NDAAs and MFV agreements are consistent with antitrust allegations commonly seen in monopolistic behavior cases.
❌ As of now, no concrete evidence has emerged to support or disprove the claim of executive poaching or delays in the launch of Infosys’s Helix platform.

📊 Prediction: What’s Next for Infosys and Cognizant?

The outcome of this legal battle could have significant implications for the future of the healthcare software market. If Infosys’s allegations hold weight, it could lead to a broader antitrust investigation into the practices of major IT service providers like Cognizant. Depending on how the court rules, it might push for regulatory changes to ensure fair competition within the industry.

Given the high stakes involved, both companies will likely double down on their defense strategies. Infosys could potentially emerge victorious, pushing for stricter regulation of Cognizant’s practices, while Cognizant may be forced to reevaluate its market strategies, especially in relation to its pricing and vendor agreements. Regardless of the outcome, this case will likely set a precedent for future antitrust litigation in the tech sector, signaling that the dominance of large players could soon face closer scrutiny.